Brief: Cytodyn Receives Positive Response From FDA In Regard To Its Phase 3, Registrational Trial In Covid-19 Critically Ill Population

Cytodyn

21/12/2021 14:04

Dec 21 (Reuters) - Cytodyn Inc  CYDY.PK :
    * CYTODYN RECEIVES POSITIVE RESPONSE FROM FDA IN REGARD TO
ITS
PHASE 3, REGISTRATIONAL TRIAL IN COVID-19 CRITICALLY ILL
POPULATION
    * CYTODYN INC - CD20 IS ALLOWED TO HAVE FOUR DOSAGES OF
LERONLIMAB
IN FIRST FOUR WEEKS VIA IV INFUSION
    * CYTODYN INC - FDA ALLOWS INTEGRATED OR META-ANALYSIS OF
PREVIOUS
TRIAL RESULTS IN CD20 FINAL ANALYSIS

Source text for Eikon:  ID:nBw3gc6xWa 
Further company coverage:  CYDY.PK